DF
SRPT icon

Dunhill Financial’s Sarepta Therapeutics SRPT Stock Holding History

Dunhill Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125 Sell
7
-1
-13% -$19 ﹤0.01% 1341
2026
Q1 		$191 Sell
8
-34
-81% -$658 ﹤0.01% 1265
2025
Q4 		$899 Buy
42
+2
+5% +$42 ﹤0.01% 847
2025
Q3 		$771 Hold
40
– – ﹤0.01% 796
2025
Q2 		$684 Hold
40
– – ﹤0.01% 820
2025
Q1 		$2.55K Sell
40
-40
-50% -$4.21K ﹤0.01% 696
2024
Q4 		$9.73K Buy
80
+40
+100% +$4.9K ﹤0.01% 387
2024
Q3 		$5K Hold
40
– – ﹤0.01% 551
2024
Q2 		$6.32K Hold
40
– – ﹤0.01% 364
2024
Q1 		$5.18K Buy
+40
New +$4.9K ﹤0.01% 316

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dunhill Financial's SRPT Position: Q2 2026 in Review

Dunhill Financial reduced its Sarepta Therapeutics (SRPT) stake by 13% in Q2 2026, selling an estimated $19 and leaving 7 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

Dunhill Financial first reported a position in SRPT in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.73K in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Dunhill Financial held 7 shares of Sarepta Therapeutics worth $125 as of Q2 2026.
  • Dunhill Financial sold 1 Sarepta Therapeutics share in Q2 2026, an estimated $19.
  • Sarepta Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1341 holding.
  • Dunhill Financial first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Dunhill Financial's Sarepta Therapeutics position peaked at $9.73K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.